Caris Life Sciences CAI
United StatesHealthcare · BiotechnologyUSD
29.08 USD (+7.3%)
13 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Caris Life Sciences is a biotechnology company focused on molecular and precision diagnostics in oncology, offering genomic and proteomic tumor profiling to guide treatment decisions.
Key points
from its scores- ✓Strong growth9.8
- ✓Very solid balance sheet7.6
- ✕Poor share-price trend0.9
- ✕Little or no dividend1.5
- ✕Demanding valuation2.7
AI analysis
bottom line, main risk, context and newsStrong growth and a sound balance sheet are positive, but the demanding valuation and negative momentum (-20.14%) suggest waiting for a better entry point.
Caris Life Sciences shows very strong revenue growth (45.40%) with a healthy balance sheet (net cash, Net Debt/EBITDA of -1.96) and high gross margins (69.85%), but its current valuation (forward P/E of 73.60, EV/EBITDA of 42.05) already discounts much of that growth, limiting attractiveness despite good financial health.
The main risk is valuation: with a forward P/E of 73.60 and an EV/EBITDA of 42.05, any disappointment in expected growth could trigger a significant correction, especially with already negative momentum.
Context and risks
No recent relevant news and no material exposure to current macro factors (rates, oil, tariffs) for a diagnostics biotech with net cash. The main risk is sector-specific regulatory risk, already reflected in the country's governance reference.
Is Caris Life Sciences stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 75% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 16.0 | 26.7 | −40% |
| EV / EBITDA | 42.0 | 14.5 | +191% |
| Price / book | 12.9 | 4.1 | +215% |
| Price / sales | 7.7 | 3.4 | +126% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 2.7 out of 10 (median for Healthcare: 4.7).
Average analyst target: 29.08 USD, +7.3% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 6.3 (sector 5.5), Growth 9.8 (sector 6.6).
Classic formulas with standard assumptions (0.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 16.0
- Forward P/E
- 73.6
- EV / EBITDA
- 42.0
- Price / book
- 12.9
- Price / sales
- 7.7
- Market cap
- 7.7B USD
- Enterprise value
- 7.3B USD
Profitability
- ROE
- 20.1%
- ROA
- 8.8%
- ROIC (approx.)
- 9.7%
- Gross margin
- 69.8%
- Operating margin
- 10.2%
- Net margin
- 10.6%
- Free cash flow
- 63.3M USD
- FCF yield
- 0.8%
- Cash conversion
- 36%
Solvency
- Total debt
- 452.4M USD
- Net debt
- −340.7M USD
- Cash
- 793.1M USD
- EBITDA
- 174.0M USD
- Net debt / EBITDA
- −1.96
- Debt / equity
- 76.45
- Current ratio
- 5.53
- Quick ratio
- 4.75
Growth
- Revenue growth
- +45.4%
- EPS (TTM)
- 1.69 USD
- EPS (forward)
- 0.37 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Analyst consensus
- Buy (13)
- Target price
- 29.08 USD
- 52-week range
- 14.19 – 33.65
Recent news
All CAI news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Caris Life Sciences
Is Caris Life Sciences stock cheap or expensive?
On P/E and EV / EBITDA, it trades 75% above the Healthcare median on average. Valuation score: 2.7 out of 10 (median for Healthcare: 4.7). Average analyst target: 29.08 USD, +7.3% versus the price. This is not investment advice.
What score does Caris Life Sciences get on MeridIAn Screener?
It scores 5.2 out of 10, rank 1,576 of 2,130 (better than 24% of the companies analysed). Its strongest category is Growth (9.8) and its weakest, Momentum (0.9). Analysis of 08/10/2026.
What is Caris Life Sciences's P/E ratio?
Its P/E is 16.0: the share price equals 16.0 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 73.6.
How much is Caris Life Sciences worth on the stock market?
Its market capitalisation is 7.7B USD and its enterprise value, debt included, is 7.3B USD.
How much debt does Caris Life Sciences have?
It has more cash than debt: net cash of 340.7M USD.
Does Caris Life Sciences pay a dividend?
It pays no dividend, or almost none.
How has Caris Life Sciences stock performed over the last year?
It has fallen 11.1% over the last year, excluding dividends. Over the last 52 weeks it has traded between 14.19 and 33.65 USD. Past performance does not guarantee future results.
What do analysts think of Caris Life Sciences?
13 analysts cover it; their average recommendation is “Buy” and their average target is 29.08 USD (+7.3% versus the price). It is an estimate, not market data.